{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:16:13Z","timestamp":1792012573955,"version":"4.4.0"},"reference-count":24,"publisher":"The Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,8,1]]},"DOI":"10.1210\/jc.2007-2803","type":"journal-article","created":{"date-parts":[[2008,6,4]],"date-time":"2008-06-04T02:38:34Z","timestamp":1212547114000},"page":"2948-2952","source":"Crossref","is-referenced-by-count":211,"title":["Severely Suppressed Bone Turnover and Atypical Skeletal Fragility"],"prefix":"10.1210","volume":"93","author":[{"given":"Maja","family":"Visekruna","sequence":"first","affiliation":[{"name":"Center for Bone Disease, Marshfield Clinic, Marshfield, Wisconsin 54449"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Wilson","sequence":"additional","affiliation":[{"name":"Center for Bone Disease, Marshfield Clinic, Marshfield, Wisconsin 54449"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fergus Eoin","family":"McKiernan","sequence":"additional","affiliation":[{"name":"Center for Bone Disease, Marshfield Clinic, Marshfield, Wisconsin 54449"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"issue":"4 Suppl 1","key":"key\n\t\t\t\t2019041114061410400_R1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2005.12.017","article-title":"Preventing osteoporosis-related fractures: an overview","volume":"119","author":"Gass","year":"2006","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t2019041114061410400_R2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1210\/er.2006-0029","article-title":"Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease.","volume":"28","author":"Chavassieux","year":"2007","journal-title":"Endocr Rev"},{"key":"key\n\t\t\t\t2019041114061410400_R3","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1056\/NEJMra040952","article-title":"Osteopetrosis.","volume":"351","author":"Tolar","year":"2004","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114061410400_R4","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1210\/jc.2006-1986","article-title":"Autosomal dominant osteopetrosis: clinical severity and natural history of 94 subjects with a chloride channel 7 gene mutation.","volume":"92","author":"Waguespack","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114061410400_R5","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1359\/jbmr.060409","article-title":"Disease status in autosomal dominant osteopetrosis type 2 is determined by osteoclastic properties.","volume":"21","author":"Chu","year":"2006","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041114061410400_R6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJMoa023110","article-title":"Bisphosphonate-induced osteopetrosis.","volume":"349","author":"Whyte","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114061410400_R7","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture.","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114061410400_R8","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy.","volume":"90","author":"Odvina","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114061410400_R9","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.bone.2007.04.198","article-title":"Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis.","volume":"41","author":"Stepan","year":"2007","journal-title":"Bone"},{"key":"key\n\t\t\t\t2019041114061410400_R10","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1359\/jbmr.070609","article-title":"Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study.","volume":"22","author":"Chapurlat","year":"2007","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041114061410400_R11","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","article-title":"Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.","volume":"100","author":"Chavassieux","year":"1997","journal-title":"J Clin Invest"},{"issue":"Suppl 1","key":"key\n\t\t\t\t2019041114061410400_R12","first-page":"S17","article-title":"Giant osteoclast formation after long-term oral aminobisphosphonate therapy for postmenopausal osteoporosis","volume":"22","author":"Weinstein","year":"2007","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041114061410400_R13","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bone.2006.01.161","article-title":"Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography.","volume":"39","author":"Borah","year":"2006","journal-title":"Bone"},{"key":"key\n\t\t\t\t2019041114061410400_R14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1359\/jbmr.070906","article-title":"Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.","volume":"23","author":"Recker","year":"2008","journal-title":"J Bone Min Res"},{"key":"key\n\t\t\t\t2019041114061410400_R15","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041114061410400_R16","first-page":"369","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws.","volume-title":"J Oral Maxillofac Surg","author":"Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws","year":"2007"},{"key":"key\n\t\t\t\t2019041114061410400_R17","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","article-title":"Oral bisphosphonate-induced osteonecrosis.","volume":"65","author":"Marx","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"key\n\t\t\t\t2019041114061410400_R18","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1302\/0301-620X.89B3.18146","article-title":"Subtrochanteric insufficiency fractures in patients on alendronate therapy.","volume":"89","author":"Goh","year":"2007","journal-title":"J Bone Joint Surg Br"},{"key":"key\n\t\t\t\t2019041114061410400_R19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00774-007-0771-y","article-title":"Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy.","volume":"25","author":"Kazuhiro","year":"2007","journal-title":"J Bone Miner Metab"},{"key":"key\n\t\t\t\t2019041114061410400_R20","first-page":"31","article-title":"Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate.","volume":"61","author":"Scheider","year":"2006","journal-title":"Geriatrics"},{"key":"key\n\t\t\t\t2019041114061410400_R21","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial long-term extension (FLEX): a randomized trial.","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041114061410400_R22","first-page":"720","article-title":"Alendronate and estrogen effects in postmenopausal women with low bone mineral density.","volume":"85","author":"Bone","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114061410400_R23","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis.","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114061410400_R24","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years experience with alendronate for osteoporosis in postmenopausal women.","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/93\/8\/2948\/9052257\/jcem2948.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T21:42:27Z","timestamp":1557610947000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/93\/8\/2948\/2598331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,1]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2007-2803","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,1]]}}}